Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executives On The Move: New CEOs Vaxil Bio and Akero Therapeutics, with Some Big Pharma Execs Joining Smaller Companies

Executive Summary

This week’s appointments include a new chief business officer at Sutro Biopharma and a new chief medical officer at Crescendo Biologics. In addition, management from AstraZeneca and Gilead Biosciences take on the CEO role at smaller firms.

You may also be interested in...



Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral

Moderna maintains its lightning pace, but questions about its Phase III trial design remain.

Coronavirus Update: Novartis Joins Vaccine Efforts With Gene Therapy Approach

Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel